February 28, 2026 a 06:00 pm
KVUE: Fundamental Ratio Analysis - Kenvue Inc.
Kenvue Inc., a subsidiary of Johnson & Johnson, operates in the consumer health sector with a diversified portfolio of well-known brands like Tylenol, Neutrogena, and Listerine. The company shows steady financial performance with a good overall score. However, its growth potential might be hindered by market saturation and strong competition in the consumer goods sector.
Fundamental Rating
Kenvue Inc.'s basic financial health is commendable, reflected in its solid scores across various parameters, suggesting a stable company with potential for steady returns.
| Evaluation Category | Score | Visual Score |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 4 | |
| Return on Assets | 4 | |
| Debt to Equity | 2 | |
| Price to Earnings | 2 | |
| Price to Book | 2 |
Historical Rating
The historical data indicates stable performance with consistent scores over time, suggesting Kenvue's steady market position.
| Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-02-27 | 3 | 5 | 4 | 4 | 2 | 2 | 2 |
| Previous | 0 | 5 | 4 | 4 | 2 | 2 | 2 |
Analyst Price Targets
Analyst forecasts suggest a conservative outlook for Kenvue with a median price target indicating moderate growth potential.
| High | Low | Median | Consensus |
|---|---|---|---|
| $22 | $17 | $18 | $18.57 |
Analyst Sentiment
The sentiment among analysts is generally neutral, with a significant number leaning towards holding the stock, which underscores a careful approach given current market conditions.
| Recommendation | Number of Analysts | Visual Representation |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 4 | |
| Hold | 10 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Kenvue Inc., with stable ratings across financial metrics, remains a solid prospect in the consumer health market. Despite the limited upside in share price, the company's strong brands provide a cushion against market volatility. Investing in KVUE may offer stable returns, though rapid growth prospects are constrained. Given the current analyst sentiment and price targets, Kenvue suits investors seeking low-risk opportunities. Caution is advised, as market dynamics can impact future performance.